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Simple Summary: Did you ever wonder why some tissues can produce very aggressive types of
cancer whereas others are apparently immune to this devastating disease? One of the most accepted
theories in the scientific community states that tumors are fueled by small numbers of key master cells
called cancer stem cells, which mediate tumor relapse and metastasis. Much effort has been made
to identify these cells by the characterization of their defining markers, in an attempt to eliminate
these cells selectively. However, many of these markers are also present in other healthy stem cells in
the body, including those found in some tissues like the dental pulp, which is known to be highly
resistant to carcinogenesis. This brings up the question of whether there is indeed a genuine marker
that can be used to unequivocally identify cancer stem cells. We set out to address this question
by a systematic comparison of healthy stem cells and cancer stem cells of different body locations,
and we discuss some key factors that play a role in the resistance of certain types of stem cells to
malignant transformation.
Abstract: The conversion of healthy stem cells into cancer stem cells (CSCs) is believed to underlie
tumor relapse after surgical removal and fuel tumor growth and invasiveness. CSCs often arise from
the malignant transformation of resident multipotent stem cells, which are present in most human
tissues. Some organs, such as the gut and the brain, can give rise to very aggressive types of cancers,
contrary to the dental pulp, which is a tissue with a very remarkable resistance to oncogenesis. In this
review, we focus on the similarities and differences between gut, brain and dental pulp stem cells and
their related CSCs, placing a particular emphasis on both their shared and distinctive cell markers,
including the expression of pluripotency core factors. We discuss some of their similarities and
differences with regard to oncogenic signaling, telomerase activity and their intrinsic propensity
to degenerate to CSCs. We also explore the characteristics of the events and mutations leading
to malignant transformation in each case. Importantly, healthy dental pulp stem cells (DPSCs)
share a great deal of features with many of the so far reported CSC phenotypes found in malignant
neoplasms. However, there exist literally no reports about the contribution of DPSCs to malignant
tumors. This raises the question about the particularities of the dental pulp and what specific barriers
to malignancy might be present in the case of this tissue. These notable differences warrant further
research to decipher the singular properties of DPSCs that make them resistant to transformation,
and to unravel new therapeutic targets to treat deadly tumors.
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1. Introduction
Adult multipotent stem cells are responsible for renewing cell populations in the different organs of
the body. The physiology and proliferative activity of these very different populations of organ-specific
stem cells are adapted to fulfil the different requirements of the host tissue. Tissues differ markedly in
their rate of mature cell turnover: there exist some tissues with high cell turnover activity owing to
very high stem cell activity, whereas others have very low rates of cell turnover owing to a relative
scarcity and/or quiescence of their adult stem cell populations.
The intestinal epithelium is the tissue with the highest adult cell renewal rate in mammals [1].
Millions of enterocytes are shed from the gut every day, which have to be replaced with new cells.
The adult intestinal epithelium is constantly renewed by a population of cells located in the base of
the Lieberkühn crypts: the ISCs, or intestinal stem cells. These are adult multipotent stem cells that
respond very quickly to regenerative niche signals, and divide every 24 h to generate a new population
of transit-amplifying cells, which gradually migrate towards the top of the villi whilst differentiating
into different cell lineages [2]. The highly proliferative activity of ISCs allows for a practically complete
replacement of the intestinal villi and crypt epithelial cells in a period of a few days. This turnover
rate may be even accelerated in the case of presence of gut parasites, where it contributes to parasite
expulsion [3].
On the diametrically opposite scenario, we find the central nervous system (CNS) with a very low
self-renewal rate. Most cells in the brain and spinal cord are postmitotic neurons and glial cells. Indeed,
the very existence of neurogenesis in the adult human brain was widely questioned by the neuroscientific
community until very recently [4]. However, nowadays it is accepted that new neurons are generated
throughout the whole life of the human brain, by activation of endogenous neural stem cells, or NSCs [5].
This natural neuron renewal process takes places mainly in a region of the limbic system called the
hippocampus, a brain structure involved in memory consolidation [6]. Gliogenesis is known to be more
widespread than neurogenesis, and it can take place in both the gray and white matter parenchyma,
to ensure the renewal of postmitotic oligodendrocytes and astrocytes [7]. Both neurogenesis and
gliogenesis are known to be relatively quiescent processes in the healthy mammal CNS, but they increase
sharply after CNS injury [8,9]. However, there is controversy about whether the exacerbated activation
of NSCs and the consequent reactive gliosis following brain injury are harmful or beneficial events for
the restoration of normal CNS function [10].
Despite the great cellular and physiological differences between the healthy gut and CNS, both
organs can give rise to very aggressive types of cancers. Colorectal cancer (CRC) is one of the most
abundant cancers in the world and develops from the epithelial cells lining the colon or rectum of
the gastrointestinal tract. As in other tumors, colon cancer cells are morphologically heterogeneous,
differing in markers expression, proliferation capacity, tumorigenicity and chemotherapy resistance [11].
Glioblastoma, on the other hand, is a type of stage IV human brain cancer with the poorest prognosis
owing to its very high ability to spread and infiltrate into brain parenchyma, thus hampering its total
eradication by conventional therapies [12–14]. Both CRC and glioblastoma have in common the ability
to relapse after surgical removal, which is attributed to the presence of cancer stem cells (CSCs) within
the tumor.
The Cancer Stem Cell theory states that tumor growth is fueled by small numbers of CSCs hidden
within the bulk of the tumor mass [15]. Much as normal cell renewal in healthy adult tissues depends
on activation and proliferation of their endogenous stem cells, cell renewal in malignant tumors would
depend on the activation of CSCs [16]. This theory explains clinical observations, such as the recurrence
of tumors after initially successful therapy, and the phenomena of tumor dormancy and metastasis [17].
Biology 2020, 9, 426 3 of 26
These CSCs or tumor-initiating cells were first described in teratocarcinomas that contained highly
tumorigenic cells that, as single cells, could differentiate into multiple non-tumorigenic cell types [18].
Accordingly, the most accepted view of the theory of CSCs and tumorigenesis is that CSCs arise
from and/or are closely related to normal adult multipotent stem cells, which undergo a process of
transformation owing to the combined effect of gene mutations and cellular niche perturbation. Thus,
understanding how adult tissue-specific stem cells behave in the healthy adult body, and how this
homeostasis is lost under specific circumstances, is of paramount importance for the study of the
different types of cancer.
The dental pulp shows a cellular renewal rate in between the gut epithelium and the brain
parenchyma. Dental pulp tissue is of relevance to carcinogenesis because no cases of malignancies
primarily originating in that location have ever been reported, at least since 1937 [19]. Back in the late
nineteenth century it was common to diagnose putative dental pulp neoplasms as “pulpitis chronica
sarcomatosa”, which was associated with bacterial infections and poor dental hygiene. However,
closer examinations later on revealed that most, if not all, of those cases were not related to malignant
neoplasms per se, but to a colonization of the exposed dental pulp space by the gingival epithelium [20].
It is unclear whether this dental pulp resistance to oncogenesis owes simply to the physical
constraints of the reduced space of the dental pulp chamber, which would prevent a minimum
tumor growth required for dissemination, or rather to other so far unknown factors [19]. The dental
pulp contains its own stem cells: dental pulp stem cells (DPSCs), which have a particularly high
self-renewal and multilineage differentiation capacity [21]. Interestingly, one surprising feature of
DPSCs is that these cells are extremely resistant to anaerobiosis and lack of nutrients, as clearly
demonstrated by some reported facts, such as their capability to survive and proliferate to confluency
after travelling for more than one week in parafilm-sealed culture flasks under ambient temperature
shipping conditions [22]. DPSCs in the healthy dental pulp are known to localize into neurovascular
bundles containing nerves and blood vessels [23] and they are responsible for renewing populations of
mature fibroblasts, odontoblasts, and myelinating Schwann cells [24]. DPSCs can generate complete
dentin–pulp complexes in vitro and in vivo [21,25,26], and are also induced to activate and proliferate
after dental injury [27].
Arguably, the tissues with the highest resemblance to the dental pulp would be embryonic
mesenchymal tissues and also adult loose connective stromal tissues. Soft stromal connective tissues can
be found distributed throughout the human body, and enriched in some particular locations including
the skin, the bone marrow, the adipose tissue, among others [28,29]. These loose connective tissues
can also give rise to soft tissue sarcomas with a very low incidence in the human population [30,31].
Notably, all of these tissues also home their own resident multipotent mesenchymal stem cells (MSCs),
which share a great deal of characteristics, but also present important differences, with DPSCs. The
systematic comparison between MSCs and DPSCs has already been the main topic of many excellent
reviews [28,32]. It is compelling that all those connective tissues with so many resemblances at the
structural and cellular level present so little rates of malignancy, which again suggests that there might
well be other factors apart from mere physical isolation that would explain the absence of human
cancers originating in the dental pulp.
In this review, we will discuss similarities and differences between three different stem cell
types arising from different embryonic origins; ISCs and their corresponding colorectal cancer stem
cells (CCSCs) from the endoderm, NSCs and their corresponding glioma stem cells (GSCs) from
neuroectoderm, MSCs and their corresponding CSCs from mesoderm, and DPSCs from the neural crest.
Their responsiveness to oncogenic signaling, expression of specific cell markers and cell pluripotency
core factors, telomerase activities, and resistance to oncogenic transformation will be addressed.
Interestingly, no dental pulp CSCs have ever been described in the scientific literature, which brings
the attention to what specific characteristics of dental pulp cell biology might be responsible for the
resistance of DPSCs to malignity. Could we attribute this to the differential expression of a particular
cellular marker, or to any other physiological characteristic? Is there any CSC marker whose lack of
Biology 2020, 9, 426 4 of 26
expression in dental pulp cells could help explain why those cells are so little tumorigenic? Finally,
is there any particular marker at all which can be regarded to be genuine of CSCs and excluded from
all the rest of normal healthy stem cells? Those were the kind of questions that we set out to address in
this review.
It should be noted that these mentioned stem cell types are able to survive and grow in vitro
using the same type of culture media (Figure 1). So, they are not so different from each other, at least in
terms of their minimum requirements of cell signaling and metabolism. Another important shared
characteristic of these cells is that the expression of stemness markers in NSCs, MSCs, DPSCs and CSCs
is normally promoted by their growth in serum-free media, whereas cell differentiation is normally
induced when switching these cells to serum-containing media [33–38].
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neuroectoderm, neural crest) can be aintaine in the same cell culture media for long periods.
Oncogenic CRC-derived S 620 colon cancer stem cells (CCSCs, left), and normal healthy neural
stem cells (NSCs) (middle) and dental pulp stem cells (DPSCs) (right) can be grown under the same
culture conditions in either the presence or absence of fetal serum. When grown on DMEM/F12
serum-free medium supplemented with basic fibroblast growth factor (bFGF) and epidermal growth
factor (EGF), CCSCs, NSCs and DPSCs generate free-floating spheres (upper row) that can be in vitro
maintained for several months. Cells from the same batches were grown in parallel with the same
medium supplemented with 10% fetal bovine serum (bottom row), and in all these cases they generated
plastic-adherent cell monolayers. Scale bars 50 µm.
2. Cell Markers and Pluripotency Core Factors
2.1. Cell Surface or Membrane Markers
Searching for similarities between different types of normal and aberrant stem cells, numerous cell
surface markers with different functions were found to be associated with the stemness characteristics
of CCSCs (see Table 1).
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Table 1. Expression of cell markers and core factors involved in cancer in ISCs, NSCs and their
corresponding CSCs, and DPSCs. Green color represents confirmed expression as reported by the
literature. Red color represents absent expression as reported by the literature. Yellow color implies that
its expression is not well defined or needs to be further studied. “+” symbol implies the existence of
expression-confirming reports, “-” symbol implies the existence of no-expression supporting reports and
question mark “?” implies that the expression of that marker has not been yet thoroughly assessed for a
particular cell type. “↑” or “↓” symbol refers to an upregulation/increase or downregulation/reduction
in its activity/expression with respect to their normal cell counterparts. ISC: intestinal stem cells. CCSC:
colorectal cancer stem cells. NSC: neural stem cells. GSC: glioblastoma stem cells. DPSC: dental pulp
stem cells. CSC: cancer stem cells.
Intestinal Neural Dental
ISC CSC/CCSC NSC CSC/GSC DPSC
CD133 + [39] + ↑ [40,41] + [42–44] + ↑ [43,45] +/- [46,47]
CD15 ? + [48] + [49,50] + [51–53] + [54]
LGR5 + [55] + [56] + [57,58] + [59] ?
CD166 + [60,61] + [61] - [62] + ↑ [63] + [64,65]
CD44 - [60] + ↑ [66] + [67] + ↑ [68–70] + [71]
CD90 - [72] + ↑ [73] - [62] + ↑ [74] + [75,76]
CXCR4 + [77] + ↑ [78] + [79] + ↑ [80] + [81]
NESTIN + [82] + ↑ [83] + [84] + ↑ [83,85] + [54,75]
MUSASHI + [86] + ↑ [87] + [88] + ↑ [89] + [90]
SOX2 ? + ↑ [91] + [52,92] + ↑ [52,93,94] + [54,75,95,96]
OCT4 ? + ↑ [97] + [98] + ↑ [93,94,99] + [54,95,96,100]
NANOG ? + ↑ [101] + [98,102,103] + ↑ [93,94] + [54,95,96,100]
PTEN + [104] + ↓ [105] + [106] + ↓ [106] + [107]
The first identified marker of stem cells and early progenitors in the mouse small intestine was CD133,
a transmembrane glycoprotein, also known as Prominin-1 [39]. More recent studies found that CD133
was also expressed in a subpopulation of CCSCs [40,108,109] and these cells were present in metastasis
and angiogenesis of colorectal adenocarcinoma [41,108]. Moreover, other reports using subcutaneous
injection into immunodeficient mice, after comparison of CD133+ versus CD133- populations showed
that CD133- ones were unable to form tumors or grow as undifferentiated tumorspheres [110]. Similarly,
CD133 was one of the first reported markers of brain CSCs [45]. This marker was identified in brain
stem cells of fetal [111] and premature infants [112] but initially reported as absent in adult human NSCs,
contrary to murine NSCs [42,43,113]. Interestingly, CD133 has been postulated as an embryonic stem
cell marker [44] and its presence or absence may suggest a different cancer origin accordingly to the
cell transcriptional profiles. CD133+ brain CSCs behave similarly to fetal neural stem cells forming
tumorspheres whereas CD133- brain CSCs display a semi adherent growth and its transcriptional profile
is similar to adult NSCs [114].
CD133 expression has not yet been thoroughly evaluated for DPSCs. One study reporting a positive
staining of DPSCs to CD133 relied exclusively on immunocytochemical characterization, which showed
no clear membrane staining [46]. Other studies reported an absence of expression, as assessed by flow
cytometry [47]. All these observations make CD133 an interesting potential marker for tumorigenic
susceptibility across different tissues, and it would be interesting to address unequivocally whether
CD133 is expressed or not in DPSC cultures, and whether this expression changes or not with different
experimental conditions. Another comprehensive flow cytometry assessment also revealed the absence
of CD133 in the more DPSC-related human bone marrow MSCs [115]. However, CD133 expression
could be detected in CSC-like cells derived from malignant fibrosarcomas [116].
All this evidence combined points to CD133 as an interesting marker to identify CSCs in a large
variety of tissues. However, some controversy remains with regard to the adoption of CD133 as
a genuine universal CSC marker [117]. CD133 expression in CSCs has been related to particularly
aggressive phenotypes but, as shown by different reports, this CD133 marker is also expressed by
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some healthy stem cell types such as ISCs and NSCs of the gut and the brain. However, it is precisely
those organs, which give rise to very aggressive types of cancers, are also the ones that apparently
show a higher basal CD133 expression in their resident stem cells, contrary to loose connective tissues,
and the dental pulp in particular. This brings another issue: may eventually a positive relationship be
established between the basal expression of CD133 in healthy stem cells and the malignity of neoplasms
arising from CSCs in different tissues? This may deserve closer investigation. For instance, if CD133
expression was more consistently and comparatively assessed between different human stem cell types
to fill in the existing information gaps, this could decisively help to clarify this question.
Another interesting surface marker of NSCs and neural CSCs is CD15, also known as SSEA-1
or Lewis X (Lex). This embryonic stem cell marker is expressed by some multipotent murine and
human stem cells, and also by human CSCs [48,49,51–54,64,65,118]. Interestingly, CD133 and CD15
coexpression in a same cell (NSC or CSC) is very rare [53,119,120] with the exception of primitive
neuroectodermal tumors which show higher clonogenicity for CD133+/CD15+ than CD133-/CD15+
cells [121]. CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses [122].
In the intestine, CD15 expression has been found in Paneth cells in the vicinity of stem cell niches [123]
but it is yet not clear whether CD15 is expressed or not by ISCs. CD15 expression is progressively
increased during colon cancer development [48]. CD15/SSEA-1 has also been found to be expressed by
both MSCs and DPSCs, as assessed by flow cytometry and RT-PCR. The expression of CD15/SSEA-1
was also found to be higher in DPSCs than in bone marrow MSCs [124]. Moreover, this embryonic
marker was clearly upregulated in DPSCs after experimental conditions that increase the stemness of
these cells, such as Wnt/ß-catenin activation [47,54]. The expression of CD15 has also been identified
in fibrosarcoma-derived cells [125]. It would also be very interesting to compare the relative levels
of CD15 expression in CSCs vs. MSCs and/or DPSCs to further validate the utility of CD15 as a
CSC marker.
Another surface receptor that is present in human NSCs and CSCs is the Leucine-rich repeat-containing
G-protein coupled receptor 5, or LGR5 [57,58]. LGR5, also known as GPR49, works as an important
regulator of canonical Wnt/ß-catenin signaling and it physically interacts with Wnt Frizzled-5/LRP6
receptors [126]. LGR5 binds to R-spondins, which are secreted Wnt activator protein ligands. The LGR5
receptor has been postulated as a widespread CSC marker [127]. Interestingly, LGR5 is required for
the tumorigenicity of glioblastoma cells [59]. LGR5 is also expressed by healthy colorectal ISCs [55]
and its expression is maintained in CCSCs [56]. LGR5 is considered an ISC cell cycle marker and is
related to survival, proliferation, and differentiation [128]. LGR5 can also mediate integrin signaling
through MyoX and integrins present at LGR5 cytonemes [129,130]. Some subsets of MSCs have been
shown to express LGR5, although the expression of this marker seems to be highly dependent on the
mesenchymal cell source [131]. The expression of LGR5 in DPSCs also remains to be fully elucidated,
although one report showed a strong expression of LRG5 in the dental pulp and the odontoblastic cell
layer of permanent teeth [132]. Notably, the loss of expression of some specific LGR5 splicing variants
has been associated with a poor prognosis in soft tissue sarcomas [133]. It is yet unclear how this
differential expression of LRG5 isoforms may promote the development of human cancers, particularly
with regard to the regulation of Wnt/ß-catenin activity.
The CD184 receptor, also known as Fusin or CXCR4, is a G-protein coupled receptor expressed by
both brain NSCs and CSCs [79,80]. CXCR4 expression increases in vivo glioma perivascular invasion
capacity [134]. In the gut, this receptor has been used as a marker to identify the CCSC population,
together with LGR5 [135]. Furthermore, colon cancer cells double positive for CD133+ and CXCR4+
exhibit metastatic potential and their presence is linked to poor prognosis [78]. CXCR4 activation
induces several cellular responses ranging from gene transcription and chemotaxis to cell survival
and proliferation [136]. CXCR4 is amply expressed by human MSCs and DPSCs, where it contributes
to stimulate their migration and chemotaxis, through activation of PI3K/AKT and Wnt/ß-catenin
pathways [81,137]. In all cases, the activation of CXCR4 in stem and/or cancer stem cells is linked to
the acquisition of a migratory cell phenotype and/or metastatic ability.
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The transmembrane glycoprotein, CD166 also known as ALCAM (activated leukocyte cell
adhesion molecule) is an adhesion protein binding to the ECM and is expressed in both ISCs and
CCSCs [60,61]. CD166 is also expressed by plastic-adherent human MSCs and DPSCs [64,65]. CD166 is
not present in NSCs, nor in neural stem-like cells induced from conversion of bone marrow stromal cells
(CD166+) [138]. The association between CD166 expression and poor prognosis of colorectal cancer
is not yet sufficiently elucidated, with studies reporting different results [139]. However, in CD133+
GSCs, CD166 has been shown to increase cellular invasion [63]. The acquired expression of CD166 in
GSCs could be associated with a higher migration and dissemination capacity, by the conversion to
a more mesenchymal-like migratory phenotype. Under this viewpoint, an increased expression of
CD166 in CCSCs could also be regarded as a contributing factor to explain the high tendency of CRC
to form secondary metastases.
There are other mesenchymal stem cell markers associated with a higher tumor invasiveness.
CD44 is a hyaluronic acid-binding surface receptor expressed in DPSCs, GSCs and CCSCs, but not in
their corresponding healthy ISCs. Thus, CD44 constitutes a marker for prediction of hepatic metastases
and poor prognosis in CRC [66–70]. CD90, also known as THY-1, is a GPI-anchored adhesion protein
of the immunoglobulin superfamily, which is another widespread mesenchymal marker related to
poor prognosis in many cancers [140]. As expected for a mesenchymal cell marker, CD90 is also
expressed by DPSCs [71,75]. CD90 is a candidate marker for GSCs, but its expression is completely
absent from healthy brain tissues [141]. Interestingly, CD90 has also been involved in the proliferation,
migration and adhesion of human glioma-associated mesenchymal stem cells [74]. The cases of CD184,
CD44, CD90 and CD166 constitute typical examples of mesenchymal surface proteins involved in cell
chemotaxis and adhesion, whose expression is associated with the emergence of CSC phenotypes and
particularly poor prognosis in many human cancers. However, because of the prominent expression of
these markers in several types of healthy stem cells, such as MSCs and DPSCs, they also could not be
considered to be genuine markers of CSCs.
2.2. Cytoplasmic Markers
One of the most prominent proteins required for self-renewal of NSCs is the intermediate filament
Nestin [142]. Nestin is also expressed in several types of cancers [143], and also by CD133+ brain
CSCs [85]. Nestin abundance is significantly correlated with prognosis, clinicopathological features
and the histological grade of the glioma in patients [83,144]. Nestin+ tumor cells have been observed
to be the origin of tumor regrowth after chemotherapeutic treatment with the alkylating agent
temozolomide [145]. With respect to CRC, Nestin expression is upregulated in stromal cells and its
knockdown inhibits migration and cell cycle arrest at S phase, thus halting cell proliferation [146].
GFP-tagged Nestin protein of several cancer cell lines including CRC revealed a high GFP expression
in proliferating endothelial cells and nascent blood vessels in the growing tumors [147]. DPSCs in vitro
are also practically 100% Nestin+ [75]. The widespread expression of neural markers by DPSCs is
associated with the neural crest origin of these cells. In fact, contrary to other mesoderm-derived
mesenchymal stem cells, such as those obtained by the bone marrow or the adipose tissue, DPSCs have
been reported to show a much better capacity to differentiate to neuronal and glial cells [75,148,149]
and these reasons partly account for the expectation raised by DPSCs as a non-conventional source
of stem cells for neural regeneration [150,151]. Another important feature of DPSCs related to their
use for neural cell therapy is their ability to secrete neurotrophic factors [75,152] and differentiate to
endoteliocytes and pericytes to generate new blood vessels within the CNS [100].
The intracellular RNA binding-protein MUSASHI is a marker of poor prognosis in many human
cancers and regarded as a putative marker for CSCs. It is known to be expressed by ISCs [86], and it is
overexpressed in CRC, where its levels correlate with other stem cell marker of the intestinal epithelium
such as ß1-integrin and LRG5, suggesting its involvement in CCSC generation [77,153]. MUSASHI is
involved in the maintenance of adult stem cell fate, and also expressed by NSCs and GSCs [40,154,155]
where it participates in enhancing tumoral cell migration [156]. MUSASHI has also been shown to be
Biology 2020, 9, 426 8 of 26
expressed by DPSCs and other stem cells of the oral cavity, and its expression was reported to increase
in response to osteogenic differentiation [90]. There exist yet no reports of MUSASHI expression in soft
tissue sarcomas.
One marker whose loss is related to poor prognosis in human cancers is the Phosphatase and
Tensin Homolog (PTEN). This enzyme is critical for stem cell maintenance and PTEN deficiencies can
cause the development of CSCs [157]. It has been observed that PTEN loss reprograms healthy stem
cells to adopt a glioblastoma stem cell-like phenotype [106]. PTEN is also involved in the migration
of precursor cells [158] and it is expressed in adult NSCs and progenitors [102,103]. Its deletion or
loss of function has been reported to alter neurogenesis and provokes cellular alterations in adult
hippocampal neural progenitor and stem cells [159]. PTEN has also been involved in the control of the
proliferation rate and number of ISCs, and similar to what is observed in other regions, the absence
or dysfunction of PTEN provokes an intestinal polyposis due to an excessive cellular proliferation
becoming a precancerous neoplasia [104].
Recent investigations show that DPSCs present unusually high levels of PTEN expression [107].
This accounts for critical differences between DPSCs and other related multipotent stem cells, such as
mesodermal MSCs. In a comparative study between DPSCs and bone marrow MSCs, the high levels
of PTEN expression naturally present in DPSCs were shown to downregulate the oncogenic PI3K/AKT
pathway, thus contributing to an increased osteo/odontogenic capacity, at the expense of a diminished
tumorigenic capacity. Remarkably, when both bone marrow MSCs and DPSCs were transfected in
parallel with pRB and CMYC oncogenes, MSCs readily acquired a tumor phenotype whereas DPSCs
could only be induced to transform when PTEN was also simultaneously inhibited [107]. Due to its
role as a tumor suppressor gene, it might be postulated that at least some of the resistance of DPSCs to
oncogenesis may be attributed to a high expression of PTEN. Another implication of this hypothesis
would be that stem cells from other body locations could also be more vulnerable to transformation
because of an insufficient PTEN expression.
2.3. Nuclear Proteins
One of the principal characteristics of CSCs that distinguish them from the rest of tumor cells is their
overexpression of nuclear transcription factors traditionally associated to stemness and pluripotency.
SOX2 is one of the principal core factors related to cell pluripotency [92] and encodes a transcription
factor member of the SRY-related HMG-box (SOX) family. In CRC, SOX2 positive cells were found
to display several characteristics of CSCs, together with a decreased expression of the intestinal
epithelial marker CDX2, contributing to a poor prognosis [91]. OCT4A is another core factor which has
been linked to chemoresistance of colon CSCs [97] and NANOG has been recently related to colony
formation and growth of CRC cells [101]. Notably, SOX2 is expressed by both healthy NSCs and
GSCs [52]. Interestingly neural progenitor cells have also been reported to express mRNA for NANOG
and OCT4 [98]. It should be taken into account that the expression of these stemness factors, together
with others such as KLF4, leads to the development of induced pluripotent stem cells (iPSCs) with
tumorigenic capacity [99] and SOX2, OCT4 and NANOG are all pluripotency markers [93] that are
found in circulating tumor cells present in the blood of patients with glioblastoma [94].
Nevertheless, it should be noted that the mere coexpression of these three markers per se does not
necessarily induce CSC-related cell phenotypes. Healthy non-tumorigenic DPSC cultures, for instance,
also show coexpression of SOX2, OCT4A and NANOG [54,160]. Moreover, the expression of these
pluripotency core factors rises in DPSCs subjected to activation of Wnt/ßcatenin signaling to enhance
their stemness potential, but without leading to cell transformation [54,95,96]. Wnt/ßcatenin signaling
was also shown to promote the maintenance of pluripotency in embryonic stem cells [118].
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3. Oncogenic Signaling
3.1. Wingless (Wg)-Related Integration Site (Wnt)
Wnt genes are extensively conserved between invertebrates and mammals, thus highlighting
the importance of this signaling pathway to regulate cell development and gene expression [161].
Once secreted, Wnt proteins bind to specific membrane Frizzled/LRP5-6 coreceptors on the target cell.
These events lead to the membrane recruitment of an intracellular multiprotein complex containing
(among others) AXIN2, APC and Glycogen Synthase Kinase-3ß, which causes the inactivation of
the latter enzyme, and the dephosphorylation and eventual accumulation of ß-catenin protein,
a fundamental transcriptional coactivator of Wnt target genes. Wnt/ß-catenin signaling can be
potentiated by simultaneous activation of LRG5 by R-spondins [126], or alternatively weakened
by other LRP5-6 ligands such as DKK-1 [162]. Many malignant cancer cells show a pathological
hyperactivation of canonical Wnt/ß-catenin signaling [163] and mutations that promote a constitutive
activation of the Wnt pathway, such as inactivation of APC or DKK-1, very often lead to colorectal
cancer [164,165]. ISCs are positive for LGR5 [55] and AXIN2 [166], which underscores the importance
of canonical Wnt signaling in controlling the homeostasis of these cells [55,166,167]. On the contrary,
the loss of Wnt function is associated with defects in epithelial cell renewal in many organs, including
the gut [168,169].
Wnt activity in NSCs regulates their homeostasis and adult hippocampal neurogenesis [170].
In human glioma cells, it has been described as an important regulator of cell proliferation [171–173].
Thus, both healthy ISCs and NSCs are sensitive to Wnt signaling, and an excessive Wnt/ß-catenin
hyperactivation is believed to promote the transformation of stem cells to CSCs in both cases [164].
This parallelism shows a common ground between ISCs, NSCs, CCSCs and GSCs [169,174–176].
Strikingly, the “need” for the Wnt pathway and the struggle this creates between cancer cells and neural
cells reaches to levels of “vampirization” in which neurons end dying from the subsequent enwrapping
and Wnt receptor depletion taken by the squeezing and invading glioma cells. Using this strategy,
cancer cells manage to increase their available space and their own proliferation and infiltration
capabilities within the brain [177]. Furthermore, Wnt activity is required for self-renewal of GSCs [178].
Taking everything into account, it is not surprising that the targeting of the Wnt pathway has been
recently regarded as a high priority for therapeutic advances [163].
Another cell type with a high sensitivity to Wnt signaling is the DPSC. It was recently shown that
even very short-term applications of Wnt-3a in DPSCs are associated with an increased self-renewal and
an enhancement of their stemness properties [54]. Moreover, the increase in multilineage differentiation
potential in DPSCs is associated with a deep remodeling of DPSC physiology at both the metabolic
and epigenetic level [95,96]. However, Wnt/ß-catenin activation caused only a modest increase in the
self-renewal capacity of DPSCs [96]. It is currently unknown whether the non-tumorigenic phenotype
of DPSCs could have any relationship with a tighter regulation of Wnt signaling, in comparison
with CCSCs or glioma CSCs [174]. It should also be taken into account that not only the tumor cells
themselves, but also stromal cells around the tumor may also secrete additional factors activating the
Wnt/ß-catenin signaling pathway, to promote tumor cell invasion and metastasis. The contribution of
stromal cells, especially fibroblasts, endothelial cells and pericytes, appears to be very relevant for the
progression of both malignant CRC and glioblastoma [179,180].
3.2. Transforming Growth Factor Beta (TGF-ß) Signaling
TGF-β superfamily signaling plays key roles in cell differentiation and proliferation [181],
and comprises over 30 different members including activins, nodals, bone morphogenetic proteins
(BMPs), and growth and differentiation factors (GDFs) (see review [182]). TGF-β pathway activity
is able to lengthen the progression of the cell cycle in aged NSCs [183]. This signaling also increases
in the neurogenic niches during aging or after a high dose of radiation inducing the quiescence of
NSCs [184]. However, it may also induce epithelial–mesenchymal transition (EMT) of normal cells to
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acquire migratory and stem cell properties [185]. TGF-ß1 protein is known to be up-regulated during
ageing, brain lesions or during neurodegeneration [186] but is also involved in the development and
progression of high-grade gliomas [187,188]. TGF-β also promotes tissue invasion, angiogenesis and
evasion from immune attack [189,190].
TGF-β signaling also regulates stemness of normal stem cells and CSCs [191]. Indeed,
during development Activin and Nodal proteins regulate NANOG expression maintaining cellular
pluripotency in human and mouse embryonic stem cells [192]. The importance of TGF-ß signaling
in the maintenance of stemness of DPSCs needs further clarification. One report showed significant
expression changes of expression in several TGF-ß-related genes after induction of DPSC differentiation
to osteo/odontoblasts by standard pharmacological protocols. Specifically, Activin A, TGF-ß1 and
TGF-ß2 expression were shown to be downregulated, but TFG-ß receptors II and III upregulated,
after DPSC osteoblastic differentiation [193].
In the large intestine, it is assumed that the TGFβ/BMP signal gradually increases along the
intestinal axis of the villi of the crypt, while the gradient towards the base of the crypt decreases,
thus inhibiting the regeneration of stem cells and supporting the differentiation of epithelial cells,
thereby playing a vital role in balancing the effect of Wnt signaling on intestinal homeostasis [194].
However, dysregulation of TGF-β signaling is involved in cell proliferation, differentiation, migration
and apoptosis, and it could lead to the development of CCSCs [195]. Interestingly, a cross-talk between
TGF-β signaling and the R-spondin/LGR5 axis was reported in CRC cells, where LGR5-induced TGF-ß
activity in tumor cells was associated with a decreased tumor invasion and metastasis [196]. However,
the activity of the TGF-β pathway in stromal cells is associated with a higher risk of metastasis in
CRC, and pharmacological inhibition of TGF-ß receptor I impairs tumor metastasis in CRC [197].
Once again, these results show the involvement of TGF-ß signaling to promote an oncogenic tissue
microenvironment and highlight the importance of the crosstalk between tumor and stromal cells to
sustain cancer malignancy.
4. Telomerase Activity
The regulation of cellular telomerase activity depends on the transcriptional control of its two
essential components, hTERC (RNA component) and hTERT (reverse transcriptase component) [198].
Wnt/β-catenin signaling was shown to have a positive regulatory effect on the expression of telomerase
reverse transcriptase (hTERT) and CSC-related proteins [199]. In turn, telomerase directly modulates
Wnt/β-catenin signaling, by activating quiescent stem cells [200]. Importantly, the emergence of
CSCs is promoted by the overexpression of hTERT [201–203]. Interestingly, it has been reported that
a mutated TERT fragment is able to induce brain cancer stemness independently of its telomerase
activity [204]. Furthermore, telomere dysfunction promotes tumorigenesis by inducing chromosomal
instability in tumor initiating cells (see review [205]). Chromosomal instability is a source of genetic
variation, favoring tumor adaptations to stressful environments and cytotoxic anticancer drugs,
contributing to the progression at multiple stages of tumor evolution [206,207]. Normally, telomerase
activity is downregulated after human brain embryonic development even in adult multipotent stem
cells [208,209]. However, multipotent stem cells such as ISCs, MSCs, DPSCs and NSCs all present a
basal telomerase activity and hTERT expression [210–213].
Brain telomerase activity in adult mice has been found to be restricted to the subventricular zone
and olfactory bulb [214]. It plays an important role in cell proliferation in the adult but not in embryonic
NSCs [215]. Telomere length has also been demonstrated to be important for neuronal differentiation
and neuritogenesis [216] (see also review [217]). Its deficiency leads to a compromised olfactory bulb
neurogenesis [215] although NSCs lose telomerase activity upon differentiation into astrocytes [218].
DPSCs also lose progressively their telomerase activity upon their spontaneous in vitro differentiation
to osteoblastic/odontoblastic cells in conditions of high culture passages [212].
It should be emphasized that telomerase is reactivated in some malignancies such as CRC and
most of brain cancers [219]. However, the mere absence of telomerase activity does not guarantee
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cellular resistance to oncogenic transformation, because CSCs may also use a mechanism of alternative
lengthening of telomeres (ALT) [220,221]. ALT preserves telomeres by homologous recombination
machinery independently of hTERT and hTERC [222]. ALT has been reported to be present in 10–15%
of human cancers, including GSCs [52,223], but also in colon cancer cells with BRCA2 deletion [224]
or hereditary and sporadic colon cancer [225]. ALT has not been reported to date in NSCs nor
ISCs, suggesting that the origin of ALT in CSCs of brain and colon cancer could also be related to a
dedifferentiation process from somatic cells [225]. ALT has not been yet reported for DPSCs. However,
this mechanism is very active in malignant tumors of mesenchymal origin [226,227]. It remains to be
studied whether the ability to activate ALT could constitute another important difference between
DPSCs and MSCs.
5. Pathways and Obstacles to Malignant Transformation: The Surprising Case of DPSCs
By making a systematic comparison between normal and cancer stem cells of different embryonic
origins, we have identified a set of differential markers that are all present in brain and gut CSCs but
absent or at least not yet well defined in other healthy stem cells (Figure 2). Interestingly, the first
conclusion of this analysis is that a surprisingly high number of CSC markers are also expressed by
some normal stem cells. DPSCs deserve an extra mention here, because up till now there exists no CSC
marker at all that has been conclusively characterized to be absent from these cells. This brings the
response to the question of the title of this manuscript, whether there was such a thing as a genuine
CSC marker. According to the available information, we can conclude that as yet there exists no such
marker, because practically all the markers mentioned in this review, that were so far regarded as more
or less specific of CSCs, are also known to be expressed by DPSCs, with the only possible exceptions of
CD133 and (less likely) LGR5.
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Figure 2. Comparison between ISCs, NSCs and DPSCs and their corresponding CSC derivatives.
For the sake of simplicity, only markers with a differential expression are shown. Many of the markers
expressed by gut and brain CSCs are also shared by normal healthy DPSCs, with the cases of CD133 and
LGR5 as the only yet unknown exceptions. Healthy NSCs and DPSCs share at least 7 differential markers
each with CSCs. ISCs show far fewer coincidences with CSCs in terms of marker presence/absence.
Despite the great similarity in marker expression between different CSCs and DPSCs, there exist
absolutely no reports showing phenotypes of CSCs originating in the dental pulp, and dental pulp
cancer incidence worldwide is 0%. Markers in green color: confirmed expression. Markers in red color:
confirmed absence of expression. Markers in yellow color: Not well defined or unknown expression.
The yearly worldwide incidence of each cancer type for 2018 is expressed as Age Standardized Rates
(ASR) per 100,000 people (pink color), as reported in [228] and [229]. Images credit: Creative Commons
License Servier Medical Art by Servier (https://smart.servier.com/). All central nervous system cancers
are considered within brain cancer rate. CRC: colorectal cancer. CCSCs: colorectal cancer stem cells.
GSC: glioblastoma stem cells.
Normal and tumor stem cells share some important features. Due to this high resemblance and
according to the CSC theory, normal healthy stem cells in the body would be the most sensitive cellular
targets to undergo malignant transformation, although this does not rule out a possible contribution
from other more differentiated types of cells. CSCs are a small subpopulation of undifferentiated
tumorigenic cells inside the tumors with malignant phenotypic characteristics [230]. In the brain,
NSCs and early progenitor cells have been reported to give origin to glioblastoma [231]. ISCs can acquire
mutations in Wnt-pathway-activating genes that may initiate cancer [232]. Furthermore, CCSCs and
brain CSCs acquire mutations in oncogenes and tumor suppressor genes such as PTEN, TP53 and
RB1, which confer them different abilities including: stemness, producing actively proliferating
cancer progenitor cells in their niches, multidrug and apoptosis resistance and enhanced DNA repair
capacity [196,233]. Other aspects that have been proposed to lead to cellular transformation are
the alteration of several signaling pathways such as EGFR and INK4a/ARF [234] or the stromal cell
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recruitment and production of proinflammatory signals in the niche [235], which is a very old concept
that has been retaken over the last decades [236,237].
One of the most intriguing questions about the dental pulp is that, contrary to many others,
this tissue is extremely unlikely to generate malignant neoplasms. The case that the dental pulp niche
would just be more protected against mutagens and inflammatory reactions does not seem to hold
very well to explain this phenomenon. For instance, dental pulpitis stands arguably as quite common
and one of the most exacerbated inflammatory reactions in the whole human body [238]. Yet for all
this evidence, there are no case reports of malignant tumors with an alleged origin in the dental pulp,
at least since 1937 [239]. DPSCs seem to be placed in a particularly disadvantageous position to face
all the looming threats that could contribute to transform a healthy stem cell to a CSCs. It could be
somehow expected that the remarkable stemness of DPSCs would also contribute to boosting their
transformation to particularly malignant cell phenotypes. DPSCs consistently express pluripotency
core factors (SOX2, OCT4, NANOG, CD15, among others); they express adhesion proteins associated
with metastasizing ability (CD44, CD90, CD166); they are highly responsive to signaling pathways
(Wnt, TFG-ß) linked to oncogenesis; they are resistant to radiation; they resist anaerobiosis; they present
hTERT activity, similar to many CSCs and contrary to many other healthy adult multipotent stem cells
in the body. However, despite all these characteristics, DPSCs show a very low tendency to transform,
not even after a forced overexpression of hTERT [240,241] and of oncogenic E7 protein from human
papillomavirus [242].
If DPSCs share so many characteristics in terms of mitogenic potential, responsiveness to signaling
pathways, and marker expression with CSCs, the next obvious question is: what makes them so
resistant to neoplastic transformation? It has been traditionally argued that the reduced dental pulp
space acts as a natural barrier preventing tumors from reaching a critical size for dissemination.
In addition, the reactive differentiation of DPSCs to dentin-producing odontoblasts upon contact with
tumor cells would trigger the sclerosis and calcification of the dental pulp chamber, thus minimizing
even further the available space for tumor growth [19]. However, there are alternative explanations,
such as a high expression of tumor-suppressor genes by DPSCs. This is clearly an aspect of DPSC
biology that has not been yet sufficiently studied. May it be that DPSCs are equipped with a better
genetic armor to avoid transformation? If we identify the genetic signatures that make DPSCs so
resistant to oncogenesis, could we try to boost those characteristics in other more vulnerable and/or
pre-neoplastic cells? We have previously shown the example of PTEN [107]. This accounts for
critical differences between DPSCs and MSCs, with regard to oncogenic susceptibility. Among tumor
suppressors expressed by DPSCs, we also include some microRNAs, such as let-7c, which are involved
in the regulation of cell growth and differentiation via IGF/MAPK pathways [243]. Another particularly
important aspect of DPSCs is their capacity to trigger very strong DNA damage responses to genotoxic
stress [244]. In a comparative assessment of DPSCs and human dermal fibroblasts exposed in parallel
to a genotoxic/cytostatic cisplatin treatment, DPSCs were found to activate the p53/p21 pathway more
potently, thus leading to cell cycle arrest and a rapid onset of senescence or apoptosis [245]. This ability
to readily shut down cell proliferation in response to DNA damage constitutes a fundamental defense
mechanism against tumorigenesis, by avoiding the expansion of cells which have a compromised
genome integrity [246].
Experimental evidence, such as the one mentioned before, demonstrates that it is very likely that
there also exist genetic and/or physiological reasons for the inexistence of human dental pulp cancer
and dental pulp CSCs. If the cancer stem cell theory holds true, then there would be a lot of valuable
lessons to be learnt from these stem cells that naturally resist to transformation. Thus, the oncology
research field might well find new inspirations by looking through the window of the dental pulp.
6. Conclusions
In this review, we have compared stem cells and cancer stem cells from different embryonic
origins. Some multipotent stem cells in the adult body are believed to transform and generate CSCs
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which fuel very aggressive tumors with very poor prognosis, whereas other adult stem cells have so far
never been involved in the generation of human cancers. The case of DPSCs is particularly intriguing
because these cells express a large number of markers that have been identified and reported as highly
characteristic of CSCs. In fact, none of those markers have yet been conclusively demonstrated to be
absent from DPSCs. It is unclear where DPSC resistance to oncogenesis may come from: whether
the physical constraints imposed by the dental pulp space, the high level of expression of certain
tumor-suppressor genes, the capacity to discard defective cell progenies by inducing potent DNA
damage responses leading to senescence/apoptosis, or a combination of all of these factors together.
These aspects warrant further research with a view to gain new knowledge on the comprehension of
stem and cancer stem cell biology. Furthermore, unraveling the mechanisms of DPSC resistance to
oncogenesis might also open new therapeutic avenues and strategies to avoid or mitigate the malignant
transformation of some deadly tumors.
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Rezáčová, M. The response of human ectomesenchymal dental pulp stem cells to cisplatin treatment.
Int. Endod. J. 2012, 45, 401–412. [CrossRef]
246. Badiola, I.; Santaolalla, F.; Garcia-Gallastegui, P.; Ana, S.-D.R.; Unda, F.; Ibarretxe, G. Biomolecular bases of the
senescence process and cancer. A new approach to oncological treatment linked to ageing. Ageing Res. Rev.
2015, 23, 125–138. [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
